Research Article

A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: A pediatric brain tumor consortium study†

  1. Susan M. Blaney MD1,*,
  2. Michael Tagen PharmD2,
  3. Arzu Onar-Thomas PhD2,
  4. Stacey L. Berg MD1,
  5. Sri Gururangan MRCP (UK)3,
  6. Kathleen Scorsone PhD1,
  7. Jack Su MD1,
  8. Stewart Goldman MD4,
  9. Mark W. Kieran MD, PhD5,
  10. Larry Kun MD2,
  11. Jim Boyett PhD2,
  12. Clinton Stewart PharmD2

Article first published online: 21 SEP 2012

DOI: 10.1002/pbc.24309

Issue

Pediatric Blood & Cancer

Pediatric Blood & Cancer

Volume 60, Issue 4, pages 627–632, April 2013

Additional Information

How to Cite

Blaney, S. M., Tagen, M., Onar-Thomas, A., Berg, S. L., Gururangan, S., Scorsone, K., Su, J., Goldman, S., Kieran, M. W., Kun, L., Boyett, J. and Stewart, C. (2013), A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: A pediatric brain tumor consortium study. Pediatr. Blood Cancer, 60: 627–632. doi: 10.1002/pbc.24309

Author Information

  1. 1

    Texas Children's Cancer Center/Baylor College of Medicine, Houston, Texas

  2. 2

    St. Jude Children's Research Hospital, Memphis, Tennessee

  3. 3

    Duke University Medical Center, Durham, North Carolina

  4. 4

    Children's Memorial Hospital, Chicago, Illinois

  5. 5

    Dana-Farber Children's Hospital Cancer Center, Boston, Massachusetts

*Texas Children's Cancer Center, 6621 Fannin, CC 1410.00, Houston, TX 77030.

  1. †

    Conflict of Interest: Nothing to declare.

Publication History

  1. Issue published online: 13 FEB 2013
  2. Article first published online: 21 SEP 2012
  3. Manuscript Accepted: 9 AUG 2012
  4. Manuscript Received: 22 MAY 2012

Funded by

  • 5 U01. Grant Number: CA81457
  • NCRR. Grant Number: M01 RR00188

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS